LVTX

LAVA Therapeutics N.V. (LVTX) | Rumor.io

LAVA Therapeutics

LVTX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about LVTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 25

LAVA Therapeutics N.V. (LVTX) is implementing a restructuring plan, including a 30% workforce reduction, to further cost-containment and cash conservation measures.
The company's cash, cash equivalents, and investments as of December 31, 2024, were $76.6 million.
LVTX has been experiencing a strong breakout, with some traders anticipating a potential run from $1.50 to $1.80.

Generated by AI

Sentiment

Of the messages about LVTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	96.3% +23.14
Bearish	—	—	—	3.7% -23.14

Bullish· Feb 25

LVTX is showing potential for further growth, with a possible breakout to $1.80.
The company's strategic options evaluation is a positive development, indicating a strong future ahead.
LVTX is experiencing a significant volume burst, with accumulation efforts and a possible launch to $1.60+.

Bearish· Mar 5

$LVTX is overbought and due for a correction, with some investors selling their shares for a profit.
The stock's recent price movement suggests that investors are taking profits, leading to selling pressure.
Short sellers are likely to continue to target $LVTX, which could lead to further price declines.

Generated by AI

Topics

Of the messages about LVTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	63.64%
Controversies	—	—	—	10.91%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	25.45%

Analysts· Apr 19

LAVA Therapeutics N.V. (LVTX) has been initiated with an "outperform" rating and a price target of $26 by SVB Leerink.
Jefferies has initiated coverage on LVTX with a "buy" rating and a price target of $23.
JP Morgan has initiated coverage on LVTX with an "overweight" rating and a price target of $22.

Announcements· Mar 5

LAVA Therapeutics (LVTX) received a $7 million milestone payment from Pfizer for clinical development progress on PF-08046052, a bispecific gamma delta T cell engager licensed from LAVA.
The milestone payment was triggered by Pfizer's achievement of a clinical development milestone for PF-08046052 in a Phase 1 study, showcasing promising advancements in immuno-oncology.
LVTX has a market capitalization of $80 million, with $104 million in cash and $6 million in debt, and is partnered with several major pharmaceutical companies, including Merck, Seagen, and Janssen.

Technical Analysis· Jan 25

$LVTX has been holding the 2.07-2.10 area well on watch in after-hours trading.
A potential double bottom is forming in $LVTX, with a bull flag on the daily chart indicating a possible breakout.
$LVTX is retesting the $2.50 level, which could be a key area for a gap up or a breakdown.

Generated by AI

Community

Of the messages about LVTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	21.76%
Newcomers	—	—	—	78.24%

Regulars· Mar 5

LAVA Therapeutics N.V. received $7 million from Pfizer as a trial for its cancer drug advances.
The company's stock, $LVTX, closed up 37.73% and traded 281% above average volume.
Pfizer has achieved a clinical development milestone for its collaboration with LAVA, with a payment of $7 million.

Newcomers· Mar 5

Newcomers to the LAVA Therapeutics N.V. (LVTX) are focused on the company's clinical development milestone achieved by Pfizer for PF-08046052, a potential breakthrough in cancer treatment.
They are highlighting the significance of the phase 1 study results, which could indicate a new direction for cancer treatment.
The newcomers are also discussing the market impact of the news, with some considering buying or selling LVTX based on the "Magic Signal" being triggered.

Generated by AI

Also Discussed

Investors talking about LVTX also mention

#	Name	Attention
1	Acumen Pharmaceuticals, Inc.ABOS	0%new
2	IN8bio, Inc.INAB	0%0
3	TCBP - TC Biopharm (Holdings) Plc	——
4	OMGA - Omega Therapeutics, Inc.	——
5	CytomX Therapeutics, Inc.CTMX	0%0
6	QRTEB - Qurate Retail, Inc.	——
7	CHEA - Chenghe Acquisition Co.	——
8	KRON - Kronos Bio, Inc.	——
9	Annexon Inc.ANNX	0%+0
10	Magnera Corp.GLT	0%0